from “sell” to potential +140%
The uncertainty surrounding Grifols and the extreme volatility its price is once again experiencing are also reflected in the recommendations issued by analyst firms following the release of their results.
The results published by Grifols do not reduce large discrepancies what analysts say about their evolution in the stock market.
Since publishing its reports last week calls for cautioneven for salecompany actions coupled with updated estimates that leave room for triple digit increase.
In the middle are firms that have chosen to avoid a clear positioning by set your price
The results published by Grifols do not reduce large discrepancies what analysts say about their evolution in the stock market.
Since publishing its reports last week calls for cautioneven for salecompany actions coupled with updated estimates that leave room for triple digit increase.
In the middle are firms that have chosen to avoid a clear positioning by place target price under review, We’re waiting for the stock market outlook to clear up more for the most punished company on all of Ibex in 2024.
As soon as possible This panorama could have dispelled some of the clouds that were in effect at the time auditor approval results of 2023. Grifols announced that this approval will occur no later than March 8.
‘Sell’
Confirmation of this auditor’s signature will alleviate the current downward pressure on Grifols. But this would not clear them completely. In fact, despite the stock market’s 50% crash this year alone, companies like Bankinter are repeating their “sell” recommendation on Grifols shares.
In its latest statement about the blood products company following its results published last week, Bankinter said that, with the exception of the auditor, “uncertainty remains regarding the aspects that seem to us most important: the contents have not been made public.” information delivered to CNMVuncertain corporate structure and commercial relationships with related parties and underlying shareholders.”
Consequently, they add from the firm: “our recommendation remains to sell and our target price remains under review.”
As justification for such caution, they recall that they continue to advise selling “since January 9 (formerly neutral), the first day when information began to emerge that called into question the reliability of their accounts,” and that Since then, Grifols has fallen 44%. on Capricorn.
‘Buy’
The specific nature of the current Grifols situation has led to an increase in the number of firms revising their target prices for Grifols following the results. Only four firms reported changes to their valuation of Grifols as a result of the reports released last week, according to data compiled by LSEG.
Of the four, the firms are the most optimistic about Grifols’ return to the stock market. Berenberg. Last Thursday, the German company revised its previous target price downward. But, despite the accepted reduction, its new estimate is 19.40 euros per share, represents Growth potential 140% relative to the level at which Ibex began today’s session.